Iterum Therapeutics plc
ITRM
$1.03
-$0.05-4.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 254.00K | -- | -- | -- | -- |
| Gross Profit | -254.00K | -- | -- | -- | -- |
| SG&A Expenses | 2.12M | 1.78M | 1.90M | 2.19M | 1.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.67M | 4.89M | 3.98M | 6.16M | 11.43M |
| Operating Income | -3.67M | -4.89M | -3.98M | -6.16M | -11.43M |
| Income Before Tax | -6.56M | -5.96M | -4.97M | -7.05M | -12.22M |
| Income Tax Expenses | 25.00K | 136.00K | 31.00K | 48.00K | 142.00K |
| Earnings from Continuing Operations | -6.58M | -6.09M | -5.00M | -7.10M | -12.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.58M | -6.09M | -5.00M | -7.10M | -12.36M |
| EBIT | -3.67M | -4.89M | -3.98M | -6.16M | -11.43M |
| EBITDA | -3.41M | -4.88M | -3.97M | -6.16M | -10.99M |
| EPS Basic | -0.25 | -0.30 | -0.30 | -0.46 | -0.94 |
| Normalized Basic EPS | -0.15 | -0.19 | -0.19 | -0.29 | -0.58 |
| EPS Diluted | -0.25 | -0.30 | -0.30 | -0.46 | -0.94 |
| Normalized Diluted EPS | -0.15 | -0.19 | -0.19 | -0.29 | -0.58 |
| Average Basic Shares Outstanding | 26.69M | 20.04M | 16.55M | 15.43M | 13.18M |
| Average Diluted Shares Outstanding | 26.69M | 20.04M | 16.55M | 15.43M | 13.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |